10 January 2020 in Medicinal Research Reviews
30 September 2021 in Briefings in Bioinformatics
Coronavirus disease 2019 (COVID-19) has impacted public health as well as societal and economic well-being. In the last two decades, various prediction algorithms and tools have been developed for predicting antiviral peptides (AVPs). The current COVID-19 pandemic has underscored the need to develop more efficient and accurate machine learning (ML)-based prediction algorithms for the rapid identification of therapeutic peptides against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Several peptide-based ML approaches, including anti-coronavirus peptides (ACVPs), IL-6 inducing epitopes and other epitopes targeting SARS-CoV-2, have been implemented in COVID-19 therapeutics. Owing to the growing interest in the COVID-19 field, it is crucial to systematically compare the existing ML algorithms based on their performances. Accordingly, we comprehensively evaluated the state-of-the-art IL-6 and AVP predictors against coronaviruses in terms of core algorithms, feature encoding schemes, performance evaluation metrics and software usability. A comprehensive performance assessment was then conducted to evaluate the robustness and scalability of the existing predictors using well-constructed independent validation datasets. Additionally, we discussed the advantages and disadvantages of the existing methods, providing useful insights into the development of novel computational tools for characterizing and identifying epitopes or ACVPs. The insights gained from this review are anticipated to provide critical guidance to the scientific community in the rapid design and development of accurate and efficient next-generation in silico tools against SARS-CoV-2.
12 June 2024 in International Journal of Biological Macromolecules
20 June 2025 in Computers in Biology and Medicine
Cell-penetrating peptides (CPPs) have gained significant attention for biomedical applications, including drug delivery and therapeutic development, due to their ability to penetrate cell membranes. The accurate prediction of CPPs is critical for accelerating the design and development of novel peptide-based therapies. Approaches for CPP prediction primarily depend on either peptide characteristic-based conventional features or one or two protein language models (PLMs), but these methods often fail to fully leverage the potential of combining diverse features. To address this limitation, we propose CPPpred-En, a prediction model that evaluates multiple conventional and PLM-based features across various machine learning classifiers, selects high-performing feature-classifier combinations, and integrates them through ensemble learning. The CPPpred-En model, which was trained on both the CPP924 and MLCPP 2.0 datasets, outperformed existing state-of-the-art predictors, achieving an accuracy (Acc) of 97.27 % and a matthews correlation coefficient (MCC) of 0.964 on the CPP924 dataset and an Acc of 96.10 % and an MCC of 0.707 on the MLCPP 2.0 dataset. The ensemble-based strategy demonstrated robustness across different datasets, highlighting the strong ability of the model to generalise. The combination of conventional and PLM features in an ensemble framework is promising approach for improving peptide-based therapeutics. The CPPpred-En model is a highly accurate and reliable tool for the identification of CPPs and their application in drug delivery and targeted therapy.
15 November 2023 in Computers in Biology and Medicine
10 January 2025 in Methods